What does this research mean for the field?

Intracolonic administration of the Rifamycin SV in situ gelling formulation CB-01-35 significantly reduces macroscopic and histological colonic damage in a rat model of oxazolone-induced acute colitis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the therapeutic efficacy of an intracolonically administered rifamycin SV in situ gelling formulation (CB-01-35) in a rat model of acute oxazolone-induced colitis.

August 22, 2026Journal of Clinical MedicineOpen Access

Intracolonic Treatment with a Rifamycin SV In Situ Gelling Formulation Ameliorates Macroscopic and Histological Damage in an Acute Rat Model of Oxazolone-Induced Colitis: A Proof-of-Concept Study

View Full Paper

Ask AI

Bookmark

Authors

KMKatia ManganoUniversity of Catania GLGian Marco LeoneUniversity of Catania RMRoberto Di MarcoUniversity of Catania

Discussion

Member takes

Implication

Preclinical animal study demonstrates reduced macroscopic and histological colonic damage following local rifamycin SV gel treatment in rats, suggesting therapeutic potential for colitis.

Key Points

To assess the therapeutic efficacy of an intracolonically administered rifamycin SV in situ gelling formulation (CB-01-35) in a rat model of acute oxazolone-induced colitis.
Acute colitis was induced in female Wistar rats using oxazolone.
Rats received 3-day intracolonic treatment with CB-01-35 (80 mg/kg), vehicle, Asacol, or dexamethasone.
Assessed outcomes included macroscopic damage score (MDS), mucosal damage area, histological score, colon weight, and clinical parameters.
CB-01-35 significantly decreased the macroscopic damage score compared to vehicle (p < 0.05) and showed a trend toward reduced mucosal damage area (p = 0.06).
Histological analysis revealed significant improvements with CB-01-35, characterized by decreased leukocyte infiltration and reduced epithelial tissue damage.
CB-01-35 produced no significant changes in body weight or colon weight, while active comparator treatments demonstrated limited or inconsistent efficacy.

Cite This Study

Mangano et al. (2026) studied this question.

synapsesocial.com/papers/6a895f53ca7ade938187dda9 https://doi.org/10.3390/jcm15166409

View Full Paper

Ask AI

Bookmark

Implication

Preclinical animal study demonstrates reduced macroscopic and histological colonic damage following local rifamycin SV gel treatment in rats, suggesting therapeutic potential for colitis.

Intracolonic Treatment with a Rifamycin SV In Situ Gelling Formulation Ameliorates Macroscopic and Histological Damage in an Acute Rat Model of Oxazolone-Induced Colitis: A Proof-of-Concept Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Intracolonic Treatment with a Rifamycin SV In Situ Gelling Formulation Ameliorates Macroscopic and Histological Damage in an Acute Rat Model of Oxazolone-Induced Colitis: A Proof-of-Concept Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider